These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7932 related articles for article (PubMed ID: 10487002)

  • 41. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
    Guida M; Latorre A; Mastria A; De Lena M
    Eur J Cancer; 1996 Apr; 32A(4):730-3. PubMed ID: 8695281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
    Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
    Suzuki Y; Aoyama N; Minamide J; Takata K; Ogata T
    Int J Clin Oncol; 2005 Jun; 10(3):204-7. PubMed ID: 15990972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
    Lattanzi SC; Tosteson T; Chertoff J; Maurer LH; O'Donnell J; LeMarbre PJ; Mott L; DelPrete SA; Forcier RJ; Ernstoff MS
    Melanoma Res; 1995 Oct; 5(5):365-9. PubMed ID: 8541728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Chemotherapy of malignant melanoma].
    Ishihara K
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
    Stein ME; Bernstein Z; Tsalic M; Drumea K; Steiner M; Sklar Z; Haim N
    Am J Clin Oncol; 2002 Oct; 25(5):460-3. PubMed ID: 12393984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential chemoimmunotherapy for metastatic melanoma.
    Richards JM
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):91-5. PubMed ID: 1948135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
    J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
    Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
    J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen.
    Feliu J; González Barón M; Chacón JI; Espinosa E; Garrido P; Castro J; Escobar Y; Colmenarejo A; Jara C; García Girón C; Espinosa J; Ordóñez A
    Cancer Chemother Pharmacol; 1996; 38(2):191-4. PubMed ID: 8616911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous alpha-interferon with polychemotherapy in advanced malignant melanoma.
    Foppoli M; Citterio G; Polastri D; Guerrieri R
    Tumori; 1995; 81(2):102-6. PubMed ID: 7778212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
    McClay EF; McClay ME
    J Clin Oncol; 1994 Mar; 12(3):617-26. PubMed ID: 8120562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary malignant melanoma of the esophagus: report of a case successfully treated with pre- and post-operative adjuvant hormone-chemotherapy.
    Naomoto Y; Perdomo JA; Kamikawa Y; Haisa M; Yamatsuji T; Kenzo A; Taguchi K; Hara K; Tanaka N
    Jpn J Clin Oncol; 1998 Dec; 28(12):758-61. PubMed ID: 9879295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
    Murren JR; DeRosa W; Durivage HJ; Davis C; Makuch R; Portlock CS
    Cancer; 1991 Mar; 67(6):1514-7. PubMed ID: 2001539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
    Christodoulou C; Bafaloukos D; Linardou H; Aravantinos G; Bamias A; Carina M; Klouvas G; Skarlos D;
    J Neurooncol; 2005 Jan; 71(1):61-5. PubMed ID: 15719277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
    Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
    Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 397.